Categories Multiple Myeloma

Small Cell Lung Cancer Market to Gain from Increased Usage of Premium-Priced Branded Therapies

MarketResearchReports.Biz presents this most up-to-date research on “OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024”. MarketResearchReports.biz has recently added a new report to its repository of pharmaceutical and healthcare documents. The report analyzes the various opportunities for the growth of the global small cell lung cancer (SCLC) market. The report, […]

Read More
Categories Multiple Myeloma

Artemisinin and breast cancer

Artemisinin, a sesquiterpene phytolactone derived from Artemisia annua, is a potent antimalarial compound with promising anticancer properties, although the mechanism of its anticancer signaling is not well understood. Artemisinin inhibited proliferation and induced a strong G1 cell cycle arrest of cultured MCF7 cells, an estrogen-responsive human breast cancer cell line that represents an early-stage cancer […]

Read More
Categories Multiple Myeloma

Tools that Assist in App Development for Multiple Platforms

”; With the rise in the demand for mobile applications and an increasing use of multiple operating systems within enterprises, the concept of app development for multiple platforms or cross platform app development is fast catching up. This process can become quite complex since every OS platform has its distinct characteristics, capabilities, and features. However, […]

Read More
Categories Cancer

Study Shows Nivolumab-Chemo Combination Improves Survival in Gastric and Esophageal Cancers

Study Shows Nivolumab-Chemo Combination Improves Survival in Gastric and Esophageal Cancers The phase 3 CheckMate-649 trial evaluating nivolumab (Opdivo) plus chemotherapy compared to chemotherapy alone as a first-line treatment of gastric and esophageal cancers met its primary endpoints of overall survival (OS) and progression-free survival (PFS), according to a Bristol Myers Squibb press release. Nivolumab […]

Read More
Categories Multiple Myeloma

Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care

Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care Daratumumab (Darzalex) therapy has led to significant improvement in response rates and progression-free survival both in combination regimens and as monotherapy across several indications in patients with multiple myeloma.1 Now, a new subcutaneous formulation, daratumumab and hyaluronidase-fihj (Darzalex FasPro), provides similar efficacy in a more convenient and […]

Read More